Your browser doesn't support javascript.
loading
BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.
Wiesweg, Marcel; Preuß, Cedric; Roeper, Julia; Metzenmacher, Martin; Eberhardt, Wilfried; Stropiep, Ursula; Wedeken, Katrin; Reis, Henning; Herold, Thomas; Darwiche, Kaid; Aigner, Clemens; Stuschke, Martin; Schildhaus, Hans-Ulrich; Schmid, Kurt W; Falk, Markus; Heukamp, Lukas; Tiemann, Markus; Griesinger, Frank; Schuler, Martin.
Afiliação
  • Wiesweg M; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany; Division of Thoracic Oncology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, Germany. Electronic address: marcel.wiesweg@uk-es
  • Preuß C; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany.
  • Roeper J; Department of Hematology and Oncology, University Department Internal Medicine-Oncology, Pius Hospital, Medical Campus University of Oldenburg, Oldenburg, Germany; Lung Cancer Network NOWEL, Oldenburg, Germany.
  • Metzenmacher M; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany; Division of Thoracic Oncology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, Germany.
  • Eberhardt W; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany; Division of Thoracic Oncology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, Germany.
  • Stropiep U; Department of Hematology and Oncology, University Department Internal Medicine-Oncology, Pius Hospital, Medical Campus University of Oldenburg, Oldenburg, Germany; Lung Cancer Network NOWEL, Oldenburg, Germany.
  • Wedeken K; Department of Hematology and Oncology, University Department Internal Medicine-Oncology, Pius Hospital, Medical Campus University of Oldenburg, Oldenburg, Germany; Lung Cancer Network NOWEL, Oldenburg, Germany.
  • Reis H; Institute of Pathology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany.
  • Herold T; Institute of Pathology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany.
  • Darwiche K; Department of Pulmonary Medicine, Section of Interventional Pneumology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, Germany.
  • Aigner C; Department of Thoracic Surgery and Endoscopy, West German Cancer Center, University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, Germany; German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.
  • Stuschke M; Department of Radiotherapy, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany; German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.
  • Schildhaus HU; Institute of Pathology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany.
  • Schmid KW; Institute of Pathology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany; German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.
  • Falk M; Institute for Hematopathology Hamburg, Hamburg, Germany; Lung Cancer Network NOWEL, Oldenburg, Germany.
  • Heukamp L; Institute for Hematopathology Hamburg, Hamburg, Germany; Lung Cancer Network NOWEL, Oldenburg, Germany.
  • Tiemann M; Institute for Hematopathology Hamburg, Hamburg, Germany; Lung Cancer Network NOWEL, Oldenburg, Germany.
  • Griesinger F; Department of Hematology and Oncology, University Department Internal Medicine-Oncology, Pius Hospital, Medical Campus University of Oldenburg, Oldenburg, Germany; Lung Cancer Network NOWEL, Oldenburg, Germany.
  • Schuler M; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany; Division of Thoracic Oncology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, Germany; German Cancer Consortium (DKTK), Partner
Eur J Cancer ; 149: 211-221, 2021 05.
Article em En | MEDLINE | ID: mdl-33872981
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Carcinoma Pulmonar de Células não Pequenas / Proteínas Proto-Oncogênicas B-raf / Antígeno B7-H1 / Receptor de Morte Celular Programada 1 / Inibidores de Checkpoint Imunológico / Neoplasias Pulmonares / Mutação Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Carcinoma Pulmonar de Células não Pequenas / Proteínas Proto-Oncogênicas B-raf / Antígeno B7-H1 / Receptor de Morte Celular Programada 1 / Inibidores de Checkpoint Imunológico / Neoplasias Pulmonares / Mutação Idioma: En Ano de publicação: 2021 Tipo de documento: Article